Acutus Medical Announces Approval of its AcQMap System and AcQMap 3D Imaging and Mapping Catheter in Japan

CARLSBAD, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced approval of its AcQMap High Resolution Imaging and Mapping System and the AcQMap 3D Imaging and Mapping Catheter in Japan. Japan is the 2^nd largest medical device market in the world and the EP Mapping and Ablation market is estimated to exceed $1.4 billion in 2022 with more than 150,000 procedures performed and grow to an estimated $1.8 billion by 2025¹. Acutus’ International Alliance partner BIOTRONIK has commenced training and early market development activities in collaboration with Acutus Medical in preparation for more significant activities in 2023.